Apollomics, a US-China Company, Raises $100 Million to Develop Cancer Therapies
publication date: Jan 7, 2019
Apollomics, a Foster City-Hangzhou innovative oncology biopharma, raised $100 million in a Series B financing, led by CMB International, a subsidiary of China Merchants Bank. Previously, Apollomics was known as CBT, the drug development spin-out of cancer CRO Crown Biosciences. In connection with the funding, the company has relocated its headquarters from Hangzhou, where it has R&D and manufacturing facilities, to Foster City, CA. OrbiMed Asia led the first financing of CBT. which was formed in 2016.The B round also included OrbiMed and several new investors. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.